MVP Share Price Performance
AU$0.71
0.30 (74.39%)
69.1% undervalued intrinsic discount
AU$2.32
Fair Value
Price AU$0.71
AnalystConsensusTarget AU$2.32
Fair ValueAU$2.32
Share PriceAU$0.71
69.1% undervalued intrinsic discount
MVP Community Narratives
AN
Fair Value AU$2.32 69.1% undervalued intrinsic discount
Targeted Pricing And Penthrox Expansion Will Broaden International Reach
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Recent MVP News & Updates
No updates
Medical Developments International Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.26
- Gross Margin
- 73.80%
- Net Profit Margin
- -78.16%
- Debt/Equity Ratio
- 0%
Medical Developments International Limited Competitors
About MVP
- Founded
- 1972
- Employees
- n/a
- CEO
- WebsiteView website
Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analgesia during short procedures. The company also distributes asthma and chronic obstructive pulmonary disease products, such space chambers, peak flow meters, portable nebulisers, and silicon face mask. The company was founded in 1972 and is headquartered in Scoresby, Australia.
Australian Market Performance
- 7 Days: 1.2%
- 3 Months: 7.7%
- 1 Year: 15.0%
- Year to Date: 7.3%
The market is up 1.2% over the last week, with the Materials sector leading the way, up 4.0%. In the last year, the market has climbed 15%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading